Content Type: Commentary & Opinion

Medicare Should Cover Weight Loss Drugs as Long as the Prices Are Affordable

March 6, 2026

Medicare Negotiation’s Drug Reformulation Problem

March 6, 2026

Global Cooperation and Early Access-Clinical Outcomes Matter

March 6, 2026

Quantifying Research and Development Expenditures in the Drug Industry

March 6, 2026

Additional Steps for Maintaining Public Trust in the FDA (Reply)

March 6, 2026

Public Returns on Public Investment: Moderna’s Violation of the Social Contract

March 6, 2026

Promoting Drug and Vaccine Innovation and Managing High Prices: Introducing a Special Symposium

March 6, 2026

Government Support of Meaningful Drug and Device Innovation: Pathways and Challenges

March 6, 2026

Addressing High Drug Prices By Reforming Pharmacy Benefit Managers

March 6, 2026

Direct-To-Consumer Drug Company Pharmacies

March 6, 2026

We Need to Talk About Values: a Proposed Framework for the Articulation of Normative Reasoning in Health Technology Assessment

March 6, 2026

Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease

March 6, 2026